Novocure Announces Organizational Changes to Prepare for Future Growth
January 19 2023 - 7:30AM
Business Wire
Novocure (NASDAQ: NVCR) today announced organizational changes
to prepare for future growth, effective Jan. 17.
Pritesh Shah, Novocure’s Chief Commercial Officer, will
transition into a new executive role as Chief Growth Officer. In
this role, Mr. Shah will have worldwide responsibilities for
product and portfolio strategy, brand management, establishing a
global framework for new launches, market access and market
intelligence. Mr. Shah will also be responsible for new indications
in the United States.
After a review of Novocure’s future needs, Ely Benaim, M.D.,
Chief Medical Officer, will step down from his role and leave the
company. Dr. Benaim will partner with Novocure’s executive
leadership team to ensure a smooth transition of responsibilities.
The company wishes Dr. Benaim the best in future endeavors. Piet
Hinoul, M.D., Ph.D., currently Senior Vice President & Head of
Global Medical Affairs, will assume the role of interim Head of
Medical to ensure business continuity as the company continues its
external search for the next Chief Medical Officer. Dr. Hinoul will
report to Mr. Shah while Novocure concludes its executive
search.
Uri Weinberg, M.D., Ph.D., currently Chief Science Officer, will
transition into a new role as Chief Innovation Officer. In this
role, Dr. Weinberg will be responsible for expanding the innovative
potential of Tumor Treating Fields therapy. Moshe Giladi, Ph.D.,
currently Senior Vice President, Preclinical Research, will assume
the role of Chief Science Officer at Novocure.
“We believe the successful readout of LUNAR marks the beginning
of a transformational period for Novocure, with multiple pivotal
studies near completion and numerous future studies preparing for
launch,” said Novocure’s Chief Executive Officer Asaf Danziger.
“Our leadership needs continue to evolve with our anticipated
growth. We are committed to ensuring we have the optimal structure
to support our employees, the business and the thousands of
patients we believe we will soon have the opportunity to treat in a
multi-indication future.”
About Novocure Novocure is a global oncology company
working to extend survival in some of the most aggressive forms of
cancer through the development and commercialization of its
innovative therapy, Tumor Treating Fields. Novocure’s
commercialized products are approved in certain countries for the
treatment of adult patients with glioblastoma, malignant pleural
mesothelioma and pleural mesothelioma. Novocure has ongoing or
completed clinical studies investigating Tumor Treating Fields in
brain metastases, gastric cancer, glioblastoma, liver cancer,
non-small cell lung cancer, pancreatic cancer and ovarian
cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements In addition to historical
facts or statements of current condition, this press release may
contain forward-looking statements. Forward-looking statements
provide Novocure’s current expectations or forecasts of future
events. These may include statements regarding anticipated
scientific progress on its research programs, clinical study
progress, development of potential products, interpretation of
clinical results, prospects for regulatory approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify
some of these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 24, 2022, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230119005132/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024